诺和诺德(NVO.US)盘前涨约6.7%，报70.72美元。消息面上，诺和诺德第一季度净销售额同比增长19%至780.87亿丹麦克朗，经营利润同比增长22%至387.91亿丹麦克朗，高于分析师平均预期的371.2亿丹麦克朗。期内减肥药Wegovy的销售额同比增长85%至173.6亿丹麦克朗，糖尿病药物Ozempic的销售额同比增长18%至327.21亿丹麦克朗。
值得注意的是，该公司表示已完成下一代肥胖症治疗药物CagriSema的最后一项关键试验，并已在美国申请批准口服司美格鲁肽25mg，有望成为首个用于治疗肥胖症的口服GLP-1治疗药物。(格隆汇)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.